Business Wire

TII

8.12.2021 10:34:09 CET | Business Wire | Press release

Share
Technology Innovation Institute’s Secure Systems Research Centre in Abu Dhabi Announces Integration of Secure PX4 Stack into RISC-V Based Drone

The Secure Systems Research Centre (SSRC) at Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the launch of its first Reduced Instruction Set Computer (RISC-V) based drone flight controller that leverages the Centre’s own secure PX4 stack. The flight marks a milestone in SSRC’s path to making RISC-V based UAV systems a reality through this successful testing and validation of the RISC-V + the secure PX4 stack system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211208005440/en/

Earlier this year, the Centre became a strategic member of RISC-V International, a non-profit organisation controlled by its members, which directs the future development and drives the adoption of RISC-V free and open Instruction Set Architecture (ISA). SSRC is focused on building an RISC-V based secure flight computer system. Today’s milestone is a major signpost on this path, with the Centre using a commercially available RISC-V development platform to port the DroneCode PX4 open source software to RISC-V.

Dr. Ray O. Johnson, CEO of TII, said: “RISC-V’s ISA is revolutionising the world of computing systems, and TII is proud to build this capability into our growing collection of breakthrough solutions that are future-proofing our world – one step at a time. We are seeing the use cases for drones and similar autonomous systems now spanning multiple sectors from e-commerce to healthcare and communication to security. This achievement will further strengthen our credibility as a global research centre at the forefront of cutting-edge technology that is working to shape an enabled and more secure world.”

Dr. Shreekant (Ticky) Thakkar, Chief Researcher, SSRC, said: “We are putting TII on the world map as leaders in pioneering Zero Trust Drone System research through this effort. The DroneCode community is the leading open-source community of PX4 Autopilot and fight controller hardware code and specification, respectively. A significant part of the work in realising this project required the porting of NuttX real-time OS and PX4 flight controller software to the RISC-V platform. SSRC has already included some of the planned security improvements into its existing PX4 software stack, and we will continue to develop this software and contribute the modifications back to open source.”

He added: “Through this milestone, we intend to highlight our regional expertise in the research and development of security for Drone and Autonomous Systems, an area that is set to have an outsized impact in shaping the Smart Cities of the future - making them safer and also significantly accelerating the opportunities for new services.”

As a follow-up, SSRC will continue to improve the security and resilience of the open source PX4 flight control software stack and NuttX real-time OS in collaboration with open source community. Furthermore, the Centre has presented a roadmap that includes improving memory protection of NuttX OS and PX4, protecting data on the removable media and utilising commercially available Root-of-Trust components.

Jukka Laitinen, Drone Software Lead Engineer and Architect at the SSRC in TII and Technical Lead for Dronecode Security Special Interest Group also presented a talk on making the current drone platform better, more secure, and resilient at the PX4 Autopilot Development Summit in September 2021.

SSRC is on track to achieving the first TII custom flight controller hardware, with the initial prototypes of this hardware, using a commercial off-the-shelf RISC-V SoC, expected by Q1 2022. This will enable researchers and industry to replace existing commercial flight controllers with a TII secure flight controller.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye